Literature DB >> 25404096

Recommendations for the management of patients with familial hypercholesterolemia.

David I Feldman1, Michael J Blaha, Raul D Santos, Steve R Jones, Roger S Blumenthal, Peter P Toth, Laurence S Sperling, Seth S Martin.   

Abstract

Familial hypercholesterolemia (FH), characterized by congenitally elevated low-density lipoprotein cholesterol levels, is estimated to affect 20 million people worldwide. In patients with heterozygous FH, coronary artery disease manifests in about half of men by age 50 and one third of women by age 60, while homozygous FH patients often suffer coronary events in the first or second decade of life. Early diagnosis and aggressive treatment are paramount. However, many FH patients remain undiagnosed and/or inadequately treated. There is a considerable need for more effective screening and diagnosis of FH in the United States. Our objective herein is to provide concise overviews of how to screen for and diagnose FH and summarize international consensus recommendations for managing adults and children with available treatments.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25404096     DOI: 10.1007/s11883-014-0473-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  49 in total

1.  Management of familial hypercholesterolemia during pregnancy: case series and discussion.

Authors:  Danny J Eapen; Kiran Valiani; Shilpa Reddy; Laurence Sperling
Journal:  J Clin Lipidol       Date:  2011-09-21       Impact factor: 4.766

Review 2.  Cholesterol, the central lipid of mammalian cells.

Authors:  Frederick R Maxfield; Gerrit van Meer
Journal:  Curr Opin Cell Biol       Date:  2010-06-02       Impact factor: 8.382

Review 3.  Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.

Authors:  Gerald F Watts; Samuel Gidding; Anthony S Wierzbicki; Peter P Toth; Rodrigo Alonso; W Virgil Brown; Eric Bruckert; Joep Defesche; Khoo Kah Lin; Michael Livingston; Pedro Mata; Klaus G Parhofer; Frederick J Raal; Raul D Santos; Eric J G Sijbrands; William G Simpson; David R Sullivan; Andrey V Susekov; Brian Tomlinson; Albert Wiegman; Shizuya Yamashita; John J P Kastelein
Journal:  Int J Cardiol       Date:  2013-11-20       Impact factor: 4.164

4.  Inheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk.

Authors:  D Meeike Kusters; Hans J Avis; Marjet J Braamskamp; Roeland Huijgen; Frits A Wijburg; John J Kastelein; Albert Wiegman; Barbara A Hutten
Journal:  J Lipid Res       Date:  2013-07-05       Impact factor: 5.922

5.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.

Authors:  Evan A Stein; Dan Gipe; Jean Bergeron; Daniel Gaudet; Robert Weiss; Robert Dufour; Richard Wu; Robert Pordy
Journal:  Lancet       Date:  2012-05-26       Impact factor: 79.321

6.  Guidelines for the management of familial hypercholesterolemia.

Authors:  Mariko Harada-Shiba; Hidenori Arai; Shinichi Oikawa; Takao Ohta; Tomoo Okada; Tomonori Okamura; Atsushi Nohara; Hideaki Bujo; Koutaro Yokote; Akihiko Wakatsuki; Shun Ishibashi; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2012-10-25       Impact factor: 4.928

7.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors:  H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal:  Am J Cardiol       Date:  1998-12-15       Impact factor: 2.778

8.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Authors:  Marina Cuchel; Emma A Meagher; Hendrik du Toit Theron; Dirk J Blom; A David Marais; Robert A Hegele; Maurizio R Averna; Cesare R Sirtori; Prediman K Shah; Daniel Gaudet; Claudia Stefanutti; Giovanni B Vigna; Anna M E Du Plessis; Kathleen J Propert; William J Sasiela; LeAnne T Bloedon; Daniel J Rader
Journal:  Lancet       Date:  2012-11-02       Impact factor: 79.321

9.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

10.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

Authors:  Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Joep C Defesche; Dick C G Basart; Anho H Liem; Jan Heeringa; Jacqueline C Witteman; Peter J Lansberg; John J P Kastelein; Eric J G Sijbrands
Journal:  BMJ       Date:  2008-11-11
View more
  1 in total

1.  Hidden Burden of Electronic Health Record-Identified Familial Hypercholesterolemia: Clinical Outcomes and Cost of Medical Care.

Authors:  Prashant Patel; Yirui Hu; Amy Kolinovsky; Zhi Geng; Jeffrey Ruhl; Sarath Krishnamurthy; Caroline deRichemond; Ayesha Khan; H Lester Kirchner; Raghu Metpally; Laney K Jones; Amy C Sturm; David Carey; Susan Snyder; Marc S Williams; Vishal C Mehra
Journal:  J Am Heart Assoc       Date:  2019-06-29       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.